论文部分内容阅读
目的:探讨Ⅲa期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者肿瘤组织中血管内皮生长因子受体(vascular endothelial growth factor receptor,VEGFR)mRNA表达水平与重组人血管内皮抑制素注射液(商品名恩度,Endostar)辅助治疗疗效的相关性。方法:通过分支DNA-液相芯片法检测29例Ⅲa期NSCLC患者组织中VEGFR mRNA表达水平,分析VEGFR1和VEGFR2基因mRNA表达水平与手术后接受恩度联合GP方案化疗患者复发转移的相关性。结果:以1年复发转移率为本研究终点,VEGFR1在复发转移组中的表达范围4.0%~86.0%,中位表达48.9%;无复发转移组中的表达范围16.1%~73.5%,中位表达52.6%,差异有统计学意义(Z=2.225,P=0.013)。VEGFR2在无复发转移组中的表达范围1.0%~93.0%,中位表达46.9%;复发转移组中的表达范围11.7%~72.6%,中位表达36.2%,差异有统计学意义(Z=2.12,P=0.017)。结论:Ⅲa期NSCLC肿瘤组织中VEGFR mRNA高表达的患者在接受恩度辅助治疗后复发转移率更低,提示VEGFR mRNA表达水平可作为恩度的疗效预测因子,可作为筛选恩度辅助治疗获益人群的指标。
OBJECTIVE: To investigate the relationship between the expression of vascular endothelial growth factor receptor (VEGFR) mRNA and the level of recombinant human endostatin in patients with stage Ⅲ a non-small cell lung cancer (NSCLC) (Trade name Endo, Endostar) adjuvant therapy efficacy. Methods: The expression of VEGFR mRNA in 29 patients with Stage Ⅲa NSCLC was detected by branched DNA microarray. The correlation between the expression of VEGFR1 and VEGFR2 mRNA and the recurrence and metastasis of patients undergoing entecavir combined with GP regimen was analyzed. Results: One year recurrence and metastasis rate was the end point of this study. The expression of VEGFR1 in the recurrence and metastasis group ranged from 4.0% to 86.0%, with a median of 48.9%. The expression range of VEGFR1 was 16.1% to 73.5% Expression was 52.6%, the difference was statistically significant (Z = 2.225, P = 0.013). The expression of VEGFR2 was 1.0% ~ 93.0% in the non-recurrence group, with a median of 46.9%. The expression range of VEGFR2 was 11.7% -72.6% in the recurrence and metastasis group, with a median of 36.2%, with a significant difference (Z = 2.12 , P = 0.017). CONCLUSIONS: The high recurrence and metastasis rate of VEGFR mRNA in Stage Ⅲa NSCLC patients after receiving Endostar-assisted therapy suggests that the expression level of VEGFR mRNA may serve as a predictor of the effect of Endostar and may be used as a screening aid The index of the crowd.